Are low-priced drugs becoming an endangered species? | CBC News
No mention of the government in this article. They promised to reduce the cost of prescriptions a year ago by 40-70 percent. Then a few months later, after being bombarded by the pharmacy industry, who showed them how much tax revenue they would lose, they decided not to lower the costs.
That warning, in its dry bureaucratic language, was contained in a new report from Canada’s drug price monitoring agency, the Patented Medicine Prices Review Board (PMPRB). The report explores the “market entry dynamics” of new drugs approved in 2016 and 2017 in Canada, the U.S. and the European Union.
“The long-term trends are alarming,” said Douglas Clark, the PMPRB’s executive director. “This is the nature of the pharmaceutical marketplace we now find ourselves in. It’s dominated by these very high-cost drugs.”